Antibody drug conjugates are increasingly being researched for the treatment of cancer. Accurate and reliable characterization of ADCs is inevitable for their development as potential therapeutic agent. Different analytical techniques have been used in order to decipher heterogeneous nature of antibody drug conjugates, enabling successful characterization. This review will summarize specially three major analytical tools i.e. UV–Vis spectroscopy, liquid chromatography, and mass spectrometry used in characterization of antibody drug conjugates. In this review, major challenges during analysis due to the inherent features of analytical techniques and antibody drug conjugates are summarized along with the modifications intended to address each challenge.
SiddiquiMRAlOthmanZARahmanN. Analytical techniques in pharmaceutical analysis: a review. Arab J Chem2013; 10: S1409–S1421.
2.
BeckAWurchTBaillyCet al.Characterization of therapeutic antibodies and related products. Analyt Chem2012; 85: 715–736.
3.
CarterPJSenterPD. Antibody-drug conjugates for cancer therapy. Canc J2008; 14: 154–169.
4.
SieversELSenterPD. Antibody-drug conjugates in cancer therapy. Ann Rev Med2013; 64: 15–29.
5.
PolakisP. Antibody drug conjugates for cancer therapy. Pharmacol Rev2016; 68: 3–19.
6.
JacksonDStoverD. Using the lessons learned from the clinic to improve the preclinical development of antibody drug conjugates. Pharmaceut Res2015; 32: 3458–3469.
7.
de GoeijBECGLambertJM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol2016; 40: 14–23.
8.
JumbeNLXinYLeiplodDDet al.Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn2010; 37: 221–242.
9.
PhillipsGDLLiGDuggerDLet al.Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody cytotoxic drug conjugate. Canc Res2008; 68: 9280–9290.
10.
StropPLiuSHDorywalskaMet al.Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol2013; 20: 161–167.
11.
ChenY. Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy. Antibody-Drug Conjug2013; 1045: 267–273.
12.
WangCChenSCarceres-CortesJet al.Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. J Chromatogr A2016; 1455: 133–139.
13.
LaguzzaBCNicholsCLBriggsSLet al.New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J Medicin Chem1989; 32: 548–555.
14.
HudeczFGarnettMCKhanTet al.The influence of synthetic conditions on the stability of methotrexate monoclonal antibody conjugates determined by reversed phase high performance liquid chromatography. Biomed Chromatogr1992; 6: 128–132.
15.
GreenfieldRSKanekoTDauesAet al.Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Canc Res1990; 50: 6600–6607.
16.
HamblettKJSenterPDChaceDFet al.Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Canc Res2004; 10: 7063–7070.
17.
LazarACWangLBlattlerWAet al.Analysis of the composition of immunoconjugates using size exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectromet2005; 19: 1806–1814.
18.
LiuBGuoHZhangJet al.In-depth characterization of a pro-antibody drug conjugate by LC-MS. Mol Pharmaceut2016; 13: 2702–2710.
19.
SiegelMMTabeiKKunzAet al.Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Analyt Chem1997; 69: 2716–2726.
20.
ZhangYLuZengPhamCet al.Preparative two-dimensional liquid chromatography/mass spectrometry for the purification of complex pharmaceutical samples. J Chromatogr A2014; 1324: 86–95.
PetrovicMHernandoMDDiaz-CruzSet al.Liquid chromatography tandem mass spectrometry for the analysis of pharmaceutical residues in environmental samples: a review. J Chromatogr A2005; 1067: 1–14.
23.
JunutulaJRRaabHClarkSet al.Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol2008; 26: 925–932.
24.
StephanJ-PChanPLeeCet al.Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconj Chem2008; 19: 1673–1683.
25.
SandersonRJHeringMAJamesSFet al.In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Canc Res2005; 11: 843–852.
26.
BzBobalyRandazzoGMRudazSet al.Optimization of non-linear gradient in hydrophobic interaction chromatography for the analytical characterization of antibody-drug conjugates. J Chromatogr A2016; 1481: 82–91.
27.
Rodriguez-AllerMGuillarmeDBeckAet al.Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase. J Pharmaceut Biomed Anal2016; 118: 393–403.
28.
BzBobalyBeckAVeutheyJLet al.Impact of organic modifier and temperature on protein denaturation in hydrophobic interaction chromatography. J Pharmaceut Biomed Anal2016; 131: 124–132.
29.
ChenBPengYValejaSGet al.Online hydrophobic interaction chromatography mass spectrometry for top-down proteomics. Analyt Chem2016; 88: 1885–1891.
30.
Birdsall RE, et al. A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography. In MAbs. Taylor & Francis, 2015; 7: 1036–1044.
31.
FoDebaeneBoeufAWagner-RoussetEet al.Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment. Analyt Chem2014; 86: 10674–10683.
32.
AdemYTSchwarzKADuenasEet al.Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconj Chem2014; 25: 656–664.
33.
Valliere-DouglassJFMcFeeWASalas-SolanoO. Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Analyt Chem2012; 84: 2843–2849.
34.
SangHLuGLiuYet al.Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. Analyt Chim Acta2017; 955: 67–78.
35.
SunMMCBeamKSCervenyCGet al.Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconj Chem2005; 16: 1282–1290.
36.
McDonaghCFTurcottEWestendorfLet al.Engineered antibody drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Design Select2006; 19: 299–307.
37.
FeketeSMolnrIGuillarmeD. Separation of antibody drug conjugate species by RPLC: A generic method development approach. J Pharmaceut Biomed Anal2017; 137: 60–69.
38.
OuyangJ. Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. Antibody-Drug Conjug2013; 1045: 275–283.
39.
AdamoMSunGQiuDet al.Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis. J Chromatogr A2016; 1481: 44–52.
40.
StollDRHarmesDCDanforthJet al.Direct identification of rituximab main isoforms and subunit analysis by online selective comprehensive two-dimensional liquid chromatography mass spectrometry. Analyt Chem2015; 87: 8307–8315.
41.
LiYet al.A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates. J Chromatogr A2015; 1393: 81–88.
42.
SandraKet al.Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. J Chromatogr B2016; 1032: 119–130.
43.
LiuAet al.Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC MS/MS approach: assay development, validation, and a case study. J Chromatogr B2015; 1002: 54–62.
44.
FlemingMSet al.A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody maytansinoid immunoconjugates. Analyt Biochem2005; 340: 272–278.
45.
Birdsall RE, et al. A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection. In MAbs. Taylor & Francis, 2016; 8: 306–317.
46.
SauerbornMvan DongenW. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody drug conjugates. BioDrugs2014; 28: 383–391.
47.
GoyonAet al.Comprehensive study on the effects of sodium and potassium additives in size exclusion chromatographic separations of protein biopharmaceuticals. J Pharmaceut Biomed Anal2016; 144: 242–251.
48.
FeketeSet al.Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J Pharmaceut Biomed Anal2014; 101: 161–173.
49.
HollanderIKunzAHamannPR. Selection of reaction additives used in the preparation of monomeric antibody calicheamicin conjugates. Bioconjug Chem2007; 19: 358–361.
50.
QuilesSet al.Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Medicin Chem2009; 53: 586–594.
51.
HeYet al.On-line coupling of size exclusion chromatography with mixed-mode liquid chromatography for comprehensive profiling of biopharmaceutical drug product. J Chromatogr A2012; 1262: 122–129.
52.
Chen X, et al. Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peak. In MAbs. Taylor & Francis, 2009; 1: 563–571.
53.
BrorsonKJiaAY. Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality. Curr Opin Biotechnol2014; 30: 140–146.
54.
KunzA. Calicheamycin derivative carrier conjugates, United States patent application publication pubno. US, 2004; 192900: A1.
55.
ChenJet al.Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody drug conjugates. Analytic Chem2013; 85: 1699–1704.
56.
MarcouxJet al.Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine linked antibody drug conjugate. Protein Sci2015; 24: 1210–1223.
57.
HuangRYCet al.Utility of ion mobility mass spectrometry for drug-to-antibody ratio measurements in antibody-drug conjugates. J Am Soc Mass Spectromet2015; 26: 1791–1794.
58.
BradyLJet al.Molecular mass analysis of antibodies by on-line SEC-MS. J Am Soc Mass Spectromet2008; 19: 502–509.
59.
PacholarzKJBarranPE. Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry. EuPA Open Proteom2016; 11: 23–27.
60.
DamenCWNet al.Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectromet2009; 20: 2021–2033.
61.
DyachenkoAet al.Tandem native mass-spectrometry on antibody drug conjugates and submillion Da antibody antigen protein assemblies on an Orbitrap EMR equipped with a high-mass quadrupole mass selector. Analyt Chem2015; 87: 6095–6102.
62.
HengelSMet al.Measurement of in vivo drug load distribution of cysteine-linked antibody drug conjugates using microscale liquid chromatography mass spectrometry. Analyt Chem2014; 86: 3420–3425.
63.
PanLYSalas-SolanoOValliere-DouglassJF. Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry. Analyt Chem2014; 86: 2657–2664.
64.
PanLYSalas-SolanoOValliere-DouglassJF. Antibody structural integrity of site-specific antibody-drug conjugates investigated by hydrogen/deuterium exchange mass spectrometry. Analyt Chem2015; 87: 5669–5676.
65.
ZmolekWet al.A simple LC/MRM MS-based method to quantify free linker-payload in antibody-drug conjugate preparations. J Chromatogr B2016; 1032: 144–148.
66.
Janin-BussatM-Cet al.Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC MS analysis. J Chromatogr B2015; 981: 9–13.
67.
BeckAet al.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Rev Proteom2016; 13: 157–183.
